Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Ejemplares similares

• Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
  por: Min Yu, et al.
  Publicado: (2021)
• Targeting PD-1/PD-L1 in lung cancer: current perspectives
  por: González-Cao M, et al.
  Publicado: (2015)
• PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
  por: Naoya Maekawa, et al.
  Publicado: (2021)
• Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
  por: Sjoerd H van der Burg, et al.
  Publicado: (2021)
• Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
  por: Yang Hu, et al.
  Publicado: (2021)